Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Correlation study on expression of GST-pi protein in brain tissue and peripheral blood of epilepsy rats induced by pilocarpine.

Authors: Deng, X  Jia, H  Yang, Z  Li, G  Sun, S 
Citation: Deng X, etal., J Huazhong Univ Sci Technolog Med Sci. 2011 Oct;31(5):701-4. doi: 10.1007/s11596-011-0586-x. Epub 2011 Oct 25.
Pubmed: (View Article at PubMed) PMID:22038365
DOI: Full-text: DOI:10.1007/s11596-011-0586-x

Previous studies have suggested that glutathione-S-transferase pi (GST-pi) over-expression in the brain tissue is associated with refractory epilepsy. However, whether the change in GST-pi level in the peripheral blood is in line with that in brain tissue remains unknown. This study examined the correlation between GST-pi in brain tissue and that in peripheral blood in rat models of pilocarpine-induced refractory epilepsy. The animals were divided into drug-resistant group and drug-responsive group according to the response to anti-epileptic drugs. GST-pi expression in brain tissue was immunohistochemically determined, while the expression of GST-pi in peripheral blood was analyzed by Western blotting. In the hippocampus and cortex, GST-pi was mainly found in the cytoplasm and membrane of neurons, and the GST-pi expression level was higher in drug-resistant group than in the drug-responsive group and saline control group (P<0.05). Moreover, there was no significant difference between responders and saline control animals (P>0.05). The change in expression of GST-pi in peripheral blood showed the same pattern as that in brain tissues, suggesting GST-pi might contribute to drug resistance in epilepsy. Importantly, the GST-pi over-expression in peripheral blood could be used as a marker for resistance to anti-epileptic agents.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 10401935
Created: 2015-10-12
Species: All species
Last Modified: 2015-10-12
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.